araag2/HINT huggingface dataset:
Clinical trial NCT00295594 (phase 3, status: completed)
Conditions: liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: tacrolimus
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 years of age or older who will undergo primary orthotopic liver or split
             liver allograft transplantation are eligible for the study. Patients receiving a liver
             transplant from cadaveric heart-beating donor with compatible AB0 blood type can be
             included.

        Exclusion Criteria:

          -  Recipient of an auxiliary graft

          -  Patient is requiring initial sequential or parallel therapy with other
             immunosuppressive antibody preparation(s).

          -  Patient is requiring ongoing dosing with corticosteroids.

          -  Patient is exhibiting symptoms of, or is having any previous history of neoplastic
             disease

          -  Patient or donor is known to be HIV positive.

          -  Patient is allergic or intolerant to study medication
Clinical trial NCT00354991 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: losartan potassium (+) hydrochlorothiazide
SMILES: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is male or female and = 18 years of age

          -  Patients with essential hypertension previously treated with antihypertensive
             medications for at least 4 weeks but did not reach the blood pressure goal

        Exclusion Criteria:

          -  History of any condition, therapy, lab abnormality or other circumstance that might
             confound the results of the study, or interfere with the patient's participation for
             the full duration of the study, such that it is not in the best interest of the
             patient/subject to participate

          -  Pregnant or breastfeeding, or expecting to conceive within the projected duration of
             the study

          -  Previous history of severe essential hypertension

          -  History of stroke or myocardial infarction (heart attack)

          -  Evidence of renal or liver disease

          -  Uncontrolled diabetes mellitus

          -  Any known bleeding disorder

          -  Known sensitivity or intolerance to the study medication (losartan or
             hydrochlorothiazide)

          -  Other antihypertensive medications or medications that may affect blood pressure
Clinical trial NCT00427648 (phase 3, status: terminated)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: alkalinized xylocaine, placebo
SMILES: CNC[C@H](O)C1=CC(O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    funding ran out, poor accrual.
  
Eligibility criteria:

        Inclusion criteria:

          -  Female patient, 18 years of age and older

          -  Overactive bladder defined as:

               -  Urinary frequency defined as eight or more voids in a 24 hour period > 50% of
                  days of the week

               -  Symptoms of urgency

               -  Symptoms of at least three months duration

        Exclusion criteria:

          -  Positive urine culture in the past month, or more than 3 episodes of bladder infection
             in the last 2 months

          -  Stress or overflow urinary incontinence (determined by clinician) if more than 14
             episodes of urinary incontinence per week; also insensate incontinence

          -  Pregnancy

          -  Seizure disorder or clinically significant renal disease, allergy to lidocaine,
             uninvestigated hematuria, or history of urinary/reproductive tract malignancy

          -  Post-void residual more than 200 cc
Clinical trial NCT00337571 (phase 3, status: completed)
Conditions: behavioral symptoms, autistic disorder
ICD codes: F84.0
Drugs: aripiprazole, placebo
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
             Text Revision (DSM-IV-TR) diagnostic criteria for AD and demonstrates serious
             behavioral problems; diagnosis confirmed by Autism, Diagnostic Interview-Revised
             (ADI-R).

          -  CGI score > = 4 AND an ABC Irritability/Agitation subscale score > = 18 at screening
             and baseline (randomization)

          -  Mental age of at least 18 months

          -  Male or female 6 to 17 years of age inclusive, at the time of randomization

        Exclusion Criteria:

          -  Patients considered treatment resistant to neuroleptic medication based on lack of
             therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks
             each

          -  Patients previously treated and not responding to aripiprazole treatment

          -  The patient is currently diagnosed with another disorder on the autism spectrum,
             including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or
             Childhood Disintegrative Disorder

          -  Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression

          -  A seizure in the past year

          -  History of severe head trauma or stroke

          -  Non-pharmacologic therapy (e.g., psychotherapy, behavior modification) should be
             stable prior to screening and consistent throughout the study
Clinical trial NCT00327015 (phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: saxagliptin, saxagliptin, metformin, placebo, pioglitazone
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Inadequate blood sugar control

          -  No current treatment with other medications to lower blood sugar

        Exclusion Criteria:

          -  Major heart, liver or kidney problems

          -  Pregnant or breast feeding
Clinical trial NCT01272232 (phase 3, status: completed)
Conditions: metabolism and nutrition disorder, obesity
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: liraglutide, liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained

          -  Subjects diagnosed with type 2 diabetes and treated with either diet and exercise
             alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination of
             the previously mentioned compounds

          -  HbA1c 7.0-10.0% (both inclusive)

          -  Body Mass Index (BMI) at least 27.0 kg/m^2

          -  Stable body weight

          -  Preceding failed dietary effort

        Exclusion Criteria:

          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl
             peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months

          -  Known proliferative retinopathy or maculopathy

          -  History of acute or chronic pancreatitis

          -  Obesity induced by drug treatment

          -  Use of approved weight lowering pharmacotherapy

          -  Previous surgical treatment of obesity

          -  History of major depressive disorder or suicide attempt

          -  Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or
             diastolic blood pressure above or equal to 100 mmHg)

          -  Screening calcitonin of 50 ng/L or above

          -  Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial
             medullary thyroid carcinoma (FMTC)

          -  Personal history of non-familial medullary thyroid carcinoma
Clinical trial NCT01008618 (phase 3, status: completed)
Conditions: chronic pain, osteoarthritis, low back pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3, M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M54.50, M54.51, M54.59
Drugs: fentanyl, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants whose pain because of osteoarthritis or low back pain is continuing for
             at least 12 weeks prior to informed consent

          -  Participants who are continuously taking a non-opioid analgesic at the normal highest
             dose or more for at least 14 consecutive days prior to informed consent, or
             participant at a certain dose (except the use on an as-needed base) on consecutive
             days

          -  Participants showing insufficient therapeutic efficacy of the non-opioid analgesic
             currently being used, and requiring a continuous opioid analgesic as per the
             investigator or sub-investigator

          -  Participants with an average pain intensity of 50 millimeter or more on the Visual
             Analog Scale (VAS) in 24-hour daily living prior to informed consent

          -  Participants who can be hospitalized to the 4th day after the initiation of titration
             period

        Exclusion Criteria:

          -  In cases of low back pain, participants with severe pain of lower extremities due to
             radiculopathy (a problem in which one or more nerves are affected) than that of low
             back pain, or participants with disc herniation (a medical condition affecting the
             spine due to trauma, lifting injuries, or idiopathic [unknown] causes) requiring an
             operation

          -  In cases of low back pain, participants with pain due to compression fracture

          -  Participants who had an operation that may affect the assessment within 30 days before
             informed consent

          -  Participants whose main cause of the pain to be assessed is considered attributable to
             psychogenic pain (physical pain that is caused, increased, or prolonged by mental,
             emotional, or behavioral factors)

          -  Participants with asthma, bradyarrhythmia (slow irregular heart beat) and severe
             respiratory function disorders
Clinical trial NCT00440622 (phase 3, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, herceptin, capecitabine (xeloda)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior
             chemotherapy received

          -  HER-2 overexpression 2+ or 3+ using IHC or FISH +

          -  Measurable disease

          -  At least one prior chemotherapy regimen

          -  Not in a prior irradiation field

          -  No patients with brain metastatic disease who has not been irradiated or uncontrolled
             brain metastatic disease after irradiation

          -  No more than 25% of myeloproductive bone marrow irradiated. More than 4 weeks since
             prior radiotherapy and recovered

          -  Age 18 - 75 year old

          -  Performance status (WHO) 0-2

          -  Life expectancy more than 12 weeks

          -  Absolute neutrophil count > 1500/mm^3, platelet count > 100000/mm^3, hemoglobin > 9
             gr/mm^3)

          -  Adequate liver (bilirubin < 2 mg/dL, SGOT/SGPT < 2 times upper limit of normal, ALP <
             3 times upper limit of normal, creatinine < 1.5 upper limit of normal

          -  Adequate cardiac function (LVEF > 50%)

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Positive pregnancy test

          -  Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce
             P-450 cytochrome

          -  Motor or sensory neuropathy > grade 1 according to NCIC toxicity criteria

          -  History of allergic reaction attributed to docetaxel

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Other concurrent uncontrolled illness

          -  Other invasive malignancy within the past 5 years except cured basal cell skin
             carcinoma and cervical carcinoma in situ
Clinical trial NCT00337610 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus (t2dm)
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day, comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus

          -  Males

          -  Females who are highly unlikely to become pregnant

          -  Patients poorly controlled while taking one or two oral antidiabetic medications

        Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

          -  Patient required insulin therapy within the prior 8 weeks

          -  Patient is on or has been taking Thiazolidinediones (TZDs) such as Actos®
             (pioglitazone) or Avandia® (rosiglitazone) or is on or has been taking Byetta®
             (exenatide) within the prior 12 weeks of the screening visit
Clinical trial NCT00257660 (phase 3, status: completed)
Conditions: cervical dystonia
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cervical dystonia with at least 18 months since onset, and previously untreated with
             botulinum toxin or previously treated with botulinum toxin type A or B with a minimum
             interval of 16 weeks since the last injection and having returned at least to their
             usual pre-treatment status

          -  TWSTRS severity, disability and total scores meeting the defined criteria at baseline

        Exclusion Criteria:

          -  Pure anterocollis or pure retrocollis

          -  In apparent remission from cervical dystonia

          -  Previous poor response to the last two botulinum toxin type A or type B treatments

          -  Being treated with type B toxin due to lack of efficacy to type A toxin or have known
             neutralizing antibodies to type A toxin
Clinical trial NCT01536262 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium + olodaterol, tiotropium + olodaterol, olodaterol
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease.

          2. Relatively stable airway obstruction with post FEV1< 80% predicted normal and post
             FEV1/FVC <70%.

          3. Male or female Japanese patients, 40 years of age or older.

          4. Smoking history of more than 10 pack years.

        Exclusion criteria:

          1. Significant disease other than COPD

          2. Clinically relevant abnormal lab values.

          3. History of asthma.

          4. Diagnosis of thyrotoxicosis

          5. Diagnosis of paroxysmal tachycardia

          6. History of myocardial infarction within 1 year of screening visit

          7. Unstable or life-threatening cardiac arrhythmia.

          8. Hospitalization for heart failure within the past year.

          9. Known active tuberculosis.

         10. Malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. History of life-threatening pulmonary obstruction.

         12. History of cystic fibrosis.

         13. Clinically evident bronchiectasis.

         14. History of significant alcohol or drug abuse.

         15. Thoracotomy with pulmonary resection

         16. Oral ß-adrenergics.

         17. Oral corticosteroid medication at unstable doses

         18. Regular use of daytime oxygen therapy for more than one hour per day

         19. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         20. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA

         22. Pregnant or nursing women.

         23. Women of childbearing potential not using a highly effective method of birth control

         24. Patients who are unable to comply with pulmonary medication restrictions

         25. Patients with narrow-angle glaucoma or micturition disorder due to prostatic
             hyperplasia etc.
Clinical trial NCT01087502 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: glimepiride, placebo, placebo, placebo, linagliptin
SMILES: [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Type 2 diabetes mellitus

          2. GFR<60 ml/min

          3. HbA1c >=7.0% to <= 10%

          4. Age >= 18 years

          5. BMI <=45 kg/m2

          6. Signed and dated written informed consent

        Exclusion criteria:

          1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent

          2. Renal impairment requiring dialysis

          3. Bariatric surgery

          4. Impaired hepatic function

          5. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors

          6. Treatment with anti-obesity drugs

          7. Treatment with SU, glinides and metformin 8 weeks prior to informed consent
Clinical trial NCT00311090 (phase 3, status: completed)
Conditions: deep venous thrombosis
ICD codes: I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8
Drugs: idrabiotaparinux sodium, idraparinux sodium, avidin, placebo (for avidin)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed acute symptomatic DVT of the lower limbs

        Exclusion Criteria:

          -  Severe concomitant diseases (e.g. renal failure, hepatic failure, uncontrolled
             hypertension)

          -  Active bleeding or high risk for bleeding.

          -  Pregnancy or childbearing potential without proper contraceptive measures.

          -  Breastfeeding

          -  Known allergy to idraparinux, SSR126517E, or egg proteins

          -  Indication of prolonged anticoagulation for other reason than DVT of the lower limbs

          -  Symptomatic pulmonary embolism (PE)

          -  Life expectancy < 6 months.
Clinical trial NCT01672762 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus patients

          -  Subject is only on a diet and exercise program or has received a single
             antihyperglycemic agent or two antihyperglycemic agents (excluding insulin) with low
             dose (≤50% of the maximum dose of each recommended dosage)

          -  Subject has a HbA1c value (JDS value) between 6.5% and 9.5% and the difference of
             HbA1c values (JDS value) within ± 1.0%

          -  BMI 20.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus

          -  Subject has received insulin within 12 weeks (84 days) before the study

          -  Subject has proliferative diabetic retinopathy

          -  Subject has a history of clinically significant renal disease such as renovascular
             occlusive disease, nephrectomy and/or renal transplant

          -  Subject with obvious dysuria caused by a neurogenic bladder or a benign prostatic
             hypertrophy

          -  Subject has a history of cerebral vascular attack, unstable angina, myocardial
             infarction, vascular intervention, and heart disease (NYHA Class III-IV) within 12
             weeks (84 days). Subject has heart disease, cerebral vascular disease which, in the
             opinion of the principal investigator or the sub-investigator, may interfere with
             treatment or evaluation of safety of this study.

          -  Female subject who is currently pregnant or lactating, or who is possibly pregnant

          -  Male and pre-menopausal Female subject who cannot use an appropriate contraception
             during the study

          -  Subject has a history of treatment with ASP1941

          -  Subject has participated in another clinical study, post marketing study, or medical
             equipment study within 12 weeks (84 days) before providing written informed consent,
             or who is currently participating in any of those studies

          -  Subject has a serum creatinine value higher than upper limit of normal range

          -  Subject has a urinary microalbumin/ urinary creatinine ratio > 300 mg/g in urinalysis

          -  Subject has uncontrolled severe hypertension (subject whose systolic blood pressure is
             > 170 mmHg or diastolic blood pressure of > 95 mmHg measured in a sitting position
             after 5 minutes of rest

          -  Subject who is judged inappropriate for enrollment into the study by the principal
             investigator or the sub-investigator